PMID- 37578904
OWN - NLM
STAT- MEDLINE
DCOM- 20230816
LR  - 20231213
IS  - 1552-9924 (Electronic)
IS  - 0091-6765 (Print)
IS  - 0091-6765 (Linking)
VI  - 131
IP  - 8
DP  - 2023 Aug
TI  - High Exposure to Perfluoroalkyl Substances and Antibody Responses to SARS-CoV-2 
      mRNA Vaccine-an Observational Study in Adults from Ronneby, Sweden.
PG  - 87007
LID - 10.1289/EHP11847 [doi]
LID - 087007
AB  - BACKGROUND: Per- and polyfluoroalkyl substances (PFAS) are widely used, 
      environmentally ubiquitous, and stable chemicals that have been associated with 
      lower vaccine-induced antibody responses in children; however, data on adults are 
      limited. The drinking water from one of the two waterworks in Ronneby, Sweden, 
      was heavily contaminated for decades with PFAS from firefighting foams, primarily 
      perfluorohexane sulfonic acid and perfluorooctanesulfonic acid (PFOS). 
      Vaccination against SARS-CoV-2 offered a unique opportunity to investigate 
      antibody responses to primary vaccination in adults who had been exposed to PFAS. 
      OBJECTIVES: Our objective was to evaluate associations between PFAS, across a 
      wide range of exposure levels, and antibody responses in adults 5 wk and 6 months 
      after a two-dose vaccination regime against SARS-CoV-2. METHODS: Adults age 20-60 
      y from Ronneby (n = 309, median PFOS serum level 47 ng/mL, fifth to 95th 
      percentile 4 - 213 ng/mL) and a group with background exposure (n = 47, median 
      PFOS serum level 4 ng/mL) received two doses of the Spikevax (Moderna) mRNA 
      vaccine. The levels of seven PFAS were measured in serum before vaccination. 
      Serum immunoglobulin G antibodies against the SARS-CoV-2 spike antigen (S-Abs) 
      were measured before vaccination and at 5 wk (n = 350) and 6 months (n = 329) 
      after the second vaccine dose. Linear regression analyses were fitted against 
      current, historical, and prenatal exposure to PFAS, adjusting for sex, age, and 
      smoking, excluding individuals with previous SARS-CoV-2-infection. RESULTS: PFAS 
      exposure, regardless of how it was estimated, was not negatively associated with 
      antibody levels 5 wk [current PFOS: - 0.5% S-Abs/PFOS interquartile range (IQR); 
      95% confidence interval (CI): - 8, 7] or 6 months (current PFOS: 3% S-Abs/PFOS 
      IQR; 95% CI: - 6, 12) after COVID-19 vaccination. DISCUSSION: Following a strict 
      study protocol, rigorous study design, and few dropouts, we found no indication 
      that PFAS exposure negatively affected antibody responses to COVID-19 mRNA 
      vaccination for up to 6 months after vaccination. 
      https://doi.org/10.1289/EHP11847.
FAU - Andersson, Axel G
AU  - Andersson AG
AUID- ORCID: 0000-0002-1215-8433
AD  - School of Public Health and Community Medicine, Institute of Medicine, 
      Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
FAU - Lundgren, Anna
AU  - Lundgren A
AD  - Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska 
      Academy, University of Gothenburg, Gothenburg, Sweden.
AD  - Department of Clinical Immunology and Transfusion Medicine, Sahlgrenska 
      University Hospital, Gothenburg, Sweden.
FAU - Xu, Yiyi
AU  - Xu Y
AD  - School of Public Health and Community Medicine, Institute of Medicine, 
      Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
FAU - Nielsen, Christel
AU  - Nielsen C
AD  - Division of Occupational and Environmental Medicine, Department of Laboratory 
      Medicine, Lund University, Lund, Sweden.
AD  - Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public 
      Health, University of Southern Denmark, Odense, Denmark.
FAU - Lindh, Christian H
AU  - Lindh CH
AD  - Division of Occupational and Environmental Medicine, Department of Laboratory 
      Medicine, Lund University, Lund, Sweden.
FAU - Pineda, Daniela
AU  - Pineda D
AD  - Division of Occupational and Environmental Medicine, Department of Laboratory 
      Medicine, Lund University, Lund, Sweden.
FAU - Cederlund, Julia
AU  - Cederlund J
AD  - Region Blekinge, Karlskrona, Sweden.
FAU - Pataridou, Elisavet
AU  - Pataridou E
AD  - Region Blekinge, Karlskrona, Sweden.
FAU - Sogaard Tottenborg, Sandra
AU  - Sogaard Tottenborg S
AD  - Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
AD  - Department of Occupational and Environmental Medicine, Copenhagen University 
      Hospital -Bispebjerg and Frederiksberg, Copenhagen, Denmark.
FAU - Ugelvig Petersen, Kajsa
AU  - Ugelvig Petersen K
AD  - Department of Occupational and Environmental Medicine, Copenhagen University 
      Hospital -Bispebjerg and Frederiksberg, Copenhagen, Denmark.
FAU - Fletcher, Tony
AU  - Fletcher T
AD  - Department of Public Health, Environments & Society, London School of Hygiene & 
      Tropical Medicine, London, UK.
FAU - Lagging, Martin
AU  - Lagging M
AD  - Department of Infectious Diseases, Institute of Biomedicine at Sahlgrenska 
      Academy, University of Gothenburg, Gothenburg, Sweden.
FAU - Bemark, Mats
AU  - Bemark M
AD  - Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska 
      Academy, University of Gothenburg, Gothenburg, Sweden.
AD  - Department of Clinical Immunology and Transfusion Medicine, Sahlgrenska 
      University Hospital, Gothenburg, Sweden.
FAU - Jakobsson, Kristina
AU  - Jakobsson K
AD  - School of Public Health and Community Medicine, Institute of Medicine, 
      Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
AD  - Occupational and Environmental Medicine, Sahlgrenska University Hospital, 
      Gothenburg, Sweden.
FAU - Li, Ying
AU  - Li Y
AD  - School of Public Health and Community Medicine, Institute of Medicine, 
      Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
LA  - eng
SI  - EudraCT/2021-000842-16
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20230814
PL  - United States
TA  - Environ Health Perspect
JT  - Environmental health perspectives
JID - 0330411
RN  - 0 (COVID-19 Vaccines)
RN  - 9H2MAI21CL (perfluorooctane sulfonic acid)
RN  - 0 (Alkanesulfonic Acids)
RN  - 0 (Vaccines)
RN  - 0 (Fluorocarbons)
SB  - IM
CIN - Environ Health Perspect. 2023 Aug;131(8):81304. PMID: 37578903
MH  - Child
MH  - Humans
MH  - Adult
MH  - Young Adult
MH  - Middle Aged
MH  - COVID-19 Vaccines
MH  - SARS-CoV-2
MH  - Sweden/epidemiology
MH  - Antibody Formation
MH  - *COVID-19/prevention & control
MH  - *Alkanesulfonic Acids
MH  - *Vaccines
MH  - *Fluorocarbons
MH  - mRNA Vaccines
PMC - PMC10424820
EDAT- 2023/08/14 18:42
MHDA- 2023/08/16 06:42
PMCR- 2023/08/14
CRDT- 2023/08/14 13:02
PHST- 2023/08/16 06:42 [medline]
PHST- 2023/08/14 18:42 [pubmed]
PHST- 2023/08/14 13:02 [entrez]
PHST- 2023/08/14 00:00 [pmc-release]
AID - EHP11847 [pii]
AID - 10.1289/EHP11847 [doi]
PST - ppublish
SO  - Environ Health Perspect. 2023 Aug;131(8):87007. doi: 10.1289/EHP11847. Epub 2023 
      Aug 14.